The deal outlined by the US and EU has multiple parts that impact the pharmaceutical industry.

In a report released today, David Bellinger from Mizuho Securities reiterated a Hold rating on Target, with a price target of $94.00. The company’s shares opened today at $94.41. Take advantage of ...

The most alarming development for Alibaba investors is the accelerating margin deterioration masked by AI revenue growth ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Fiserv, Inc. (NYSE:FI) is included in our list of the 10 Most Oversold AI Stocks to Buy Now. On July 29, 2025, Mizuho reduced its price target on Fiserv, Inc. (NYSE:FI) from $194 to $165, maintaining ...

EPAM Systems, Inc. (NYSE:EPAM) ranks among the top robotics to buy according to analysts. Mizuho kept its Outperform rating ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

If you're looking to buy a stock that trades for less than $10 per share, you should be aware that you're taking on extra ...

Boston Scientific Corporation (NYSE:BSX) ranks among the top robotics to buy according to analysts. Mizuho kept its ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $39.62, a high estimate of $77.00, and a low estimate of $19.80. This current ...

Investing.com - Monness, Crespi, Hardt has reiterated its Sell rating on MicroStrategy (NASDAQ: MSTR) with a price target of $175.00, maintaining its bearish outlook on the Bitcoin-focused company.